Skip to main content
. 2022 Mar 16;12(5):1266–1281. doi: 10.1158/2159-8290.CD-21-1136

Figure 2.

Figure 2. Oncomap of potentially actionable alterations and canonical fusions in CNS tumors in 118 patients with 119 samples. Tumor types with five or fewer samples are grouped together in “Other.” Only alterations identified five or more times within the whole study are reported here. ATRT, atypical teratoid rhabdoid tumor; GCT, CNS germ cell tumor; EPD, ependymoma; HGG, high-grade glioma; LGG, low-grade glioma; MB, medulloblastoma; Other, other CNS tumors; supra, supratentorial; subpathology, pathology subtype; matched, matched therapy received according to recommendations; NA, not applicable; NCFUP, follow-up < 12 months.

Oncomap of potentially actionable alterations and canonical fusions in CNS tumors in 118 patients with 119 samples. Tumor types with five or fewer samples are grouped together in “Other.” Only alterations identified five or more times within the whole study are reported here. ATRT, atypical teratoid rhabdoid tumor; EPD, ependymoma; GCT, CNS germ cell tumor; HGG, high-grade glioma; LGG, low-grade glioma; matched, matched therapy received according to recommendations; MB, medulloblastoma; NA, not applicable; NCFUP, follow-up < 12 months; Other, other CNS tumors; subpathology, pathology subtype; supra, supratentorial.